(redirected from iron dextran)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to iron dextran: iron sucrose, iron dextran injection
References in periodicals archive ?
An iron overload model was successfully established by injecting with iron dextran and was able to modify hematology change.
Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy.
When the mice were injected with 25 mg/mL iron dextran for 4 weeks, the calcein AM fluorescence intensity of BMMNC in the iron overload (Fe) group (MFI: 229, 774 [+ or -] 28,423) was lower than the control group (MFI: 496,300 [+ or -] 76,698; P<0.05; Figure 1A), which indicated a higher LIP level in the bone marrow of Fe group mice.
(38), it was concluded that IS injection is a safe and effective method in the management of anemia in patients who are sensitive to iron dextran, and it can be administered without a test dose by IV push or infusion.
Iron dextran, a high molecular weight iron compound, was used extensively in the past but its use was associated with life threatening anaphylaxis.
Parenteral therapy like iron dextran and blood transfusion is indicated in those patients who cannot take oral therapy.
Iron dextran 0.4 ml i/v in D25 daily followed by weekly injection 1 ml i/m, parenteral Aminoacid solution 40 ml i/v, Inj.
Currently, four IV iron preparations are being used in the U.S.: iron dextran, ferric gluconate, ferumoxytol, and iron sucrose.
There are four intravenous (IV) iron products available in Canada: Iron Dextran (Infufer [Sandoz Canada Inc.], DexIron [Lutipold Pharmaceuticals Inc.]), Iron Sucrose (Venofer [Genpharm Inc.]), Sodium Ferric Gluconate (Ferrlecit [Sanofi-Aventis Canada Inc.]) and Ferumoxytol (Feraheme [Takeda Canada Inc.]).
TABLE Differential diagnosis of HH (5) Chronic liver disease Alcoholic and nonalcoholic steatohepatitis Hepatitis B Hepatitis C Porphyria cutanea tarda Secondary iron overload Iron-loading anemia Anemia sideroblastica Aplastic anemia Chronic hemolytic anemia Thalassemia major Parenteral iron overload Iron dextran injections Long-term hemodialysis Red blood cell transfusions Dysmetabolic iron overload syndrome
We have shown the safety and efficacy of complete replacement dosing using 1000 mg of low molecular weight iron dextran administered as a 1-h infusion in a host of conditions associated with iron lack.
For the safety outcome, a retrospective chart review was done of all ND-CKD patients who received iron dextran (INFeD) between January 2001 and November 2005 in the outpatient CKD clinic at Henry Ford Hospital, Detroit, Michigan.